Press Release – New York, NY – July 16, 2025 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT), a clinical-stage biotechnology company, in its recently priced $15 million public offering.
ThinkEquity acted as the sole placement agent for the offering.
The SRFC team was led by partners Gregory Sichenzia and Avital Perlman, with associates Christian Lichtenberger and Benasz Hansotia.
